Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma - MedCity News
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well.| MedCity News
